A Randomized, Open-label Study of the Effect of Paclitaxel, Doxorubicin, and CMF Neoadjuvant Chemotherapy, With and Without Herceptin, on Tumor Response in Women With HER2-positive Breast Cancer
收藏DataCite Commons2025-06-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008284/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This study will assess the efficacy and safety of adding Herceptin to a paclitaxel-containing
regimen followed by cyclophosphamide/methotrexate/fluorouracil (CMF) chemotherapy in women
with locally advanced breast cancer and HER2/c-erbB-2 gene amplification. In a parallel
observational study patients with HER2-negative disease will receive the same chemotherapy
without Herceptin.
提供机构：
Vivli
创建时间：
2022-07-19
